Disclaimer: You are now leaving www.beiresources.org and are going to a website that is not operated by BEI Resources. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE: BEI Resources offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the BEI Resources website and will be redirected to another site. These sites are not under the control of BEI Resources. BEI Resources is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Please read third party privacy and security policies closely as these may be different than BEI Resources policies. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
Are you sure you would like to be notified when the item is available?
Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
ARP-11545 is a subtype A envelope sequence variant that was isolated from a woman who acquired HIV-1 sexually. env was cloned directly from peripheral blood mononuclear cells (PBMCs) genomic DNA at an estimated 56 days post-infection (GenBank: AF407149). The construct consists of approximately 9000 base pair pCI-neo (Promega) backbone with an approximately 3000 base pair insertion and contains the genes for ampicillin and neomycin resistance.
ARP-11545 can be used for screening vaccine sera for neutralizing antibodies that can block recently transmitted subtype A variants. It may also be used for screening candidate microbicides.
Note: The recommend host is STBL3.
Each vial of ARP-11545 contains approximately 4 µg of dried, purified DNA stabilized in DNAstable®Plus (Biomatrica®). Please refer to the appropriate data sheet for lot-specific information.
Long, E. M., et al. “HIV Type 1 Variants Transmitted to Women in Kenya Require the CCR5 Co-Receptor for Entry Regardless of the Genetic Complexity of the Infecting Virus.” AIDS Res. Hum. Retroviruses 18 (2002): 567-576. PubMed:12036486 . Blish, C. A., et al. “HIV-1 Subtype A Envelope Variants from Early in Infection Have Variable Sensitivity to Neutralization and to Inhibitors of Viral Entry.” AIDS 21(2007): 693-702. PubMed: 17413690.
Scientists at for-profit institutions or who intend commercial use of this reagent must contact the Office of Business Development & Strategy, Email: MTA@fredhutch.org, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.
When applying for permits and forms please:
Do NOT reference BEI Resources or ATCC Catalog Numbers in the Material Description fields found on the permits and/or forms.
Make sure your name and address on the permit applications and/or forms are exactly as they appear on your BEI Resources registration.
Information about permits is provided as a courtesy to BEI Resources customers. While we use reasonable efforts to include accurate and up-to-date information on this page, we make no warranties or representation as to its accuracy.
For more information on the necessary compliance requirements associated with the biological materials provided by BEI Resources, please select this link: Compliance Requirements.